Gastrodin micro-infusion into hypothalamic PVN reverses hypertension in SHRs by modulating PPAR-γ/NF-κB/NLRP3 signaling
Background
Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases, yet current therapeutic strategies often fall short or have significant side effects. The hypothalamic paraventricular nucleus (PVN) plays a critical role in autonomic regulation of blood pressure and fluid homeostasis, making it a promising target for intervention. While Gastrodin, a compound from traditional Chinese medicine, has shown neuroprotective properties and potential in hypertension, its precise molecular mechanisms in lowering blood pressure, particularly within the PVN, have remained largely unknown. This study aimed to elucidate how Gastrodin influences key inflammatory and oxidative stress pathways in this crucial brain region.
Study Design
Researchers investigated the effects of Gastrodin in Spontaneous Hypertensive Rats (SHRs) and normotensive Wistar Kyoto (WKY) rats. Gastrodin or vehicle (artificial cerebrospinal fluid, aCSF) was directly infused into the PVN via a mini osmotic pump for 28 days. Four groups were established: WKY + PVN vehicle, WKY + PVN Gastrodin, SHR + PVN vehicle, and SHR + PVN Gastrodin. Blood pressure and heart rate were monitored throughout the study. At the conclusion, plasma and PVN tissue samples were collected for ELISA, PCR, Western blotting, and Immunofluorescence analyses to assess molecular changes.
Results
SHRs exhibited elevated blood pressure (BP), heart rate (HR), and plasma norepinephrine (NE), confirming their hypertensive status. PVN micro-infusion of Gastrodin markedly reversed these hypertensive features in SHRs, bringing BP and HR closer to WKY levels. At the molecular level, Gastrodin significantly attenuated local production of reactive oxygen species (ROS) within the PVN. It also reduced NADPH Oxidases (NOX)2 and NOX4 messenger RNA (mRNA) levels, which are key contributors to oxidative stress. Furthermore, Gastrodin attenuated the activation of PPAR-γ in the PVN. This intervention also led to a significant reduction in inflammasome activation and the expression of interleukin-1β (IL-1β).
Key Findings
- Gastrodin micro-infusion into the PVN markedly reversed elevated blood pressure and heart rate in SHRs.
- Gastrodin attenuated local reactive oxygen species (ROS) production in the PVN of SHRs.
- Gastrodin reduced
NOX2andNOX4mRNA levels in the PVN. - Gastrodin attenuated
PPAR-γactivation and reducedNF-κBandNLRP3inflammasome activation in the PVN. - Gastrodin reduced the expression of
IL-1β,MCP-1,caspase-1 p10,p-IKK/IKK, andp-p65/p65in the PVN of SHRs.
Why It Matters
This study provides compelling evidence that Gastrodin can directly target central nervous system pathways to ameliorate hypertension, highlighting the hypothalamic PVN as a critical therapeutic site. The findings suggest that Gastrodin's neuroprotective and anti-inflammatory properties extend to cardiovascular regulation, offering a novel mechanism for blood pressure control. This could pave the way for developing new hypertension treatments, potentially as an adjunctive therapy, by focusing on the PPAR-γ/NF-κB/NLRP3 axis. While a human protocol is far off, this research informs the potential for centrally acting compounds to manage complex conditions like hypertension, especially those with an inflammatory component. Targeting specific brain regions with compounds like Gastrodin could offer a more precise approach to managing hypertension, reducing systemic side effects.
gastrodin
hypertension
pv-nucleus
inflammation
oxidative-stress
preclinical-animal